PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients
Author Information
Author(s): Harwood C A, Attard N R, O'Donovan P, Chambers P, Perrett C M, Proby C M, McGregor J M, Karran P
Primary Institution: Centre for Cutaneous Research and Department of Dermatology, Institute of Cell and Molecular Science, Bart's and The London, Queen Mary School of Medicine and Dentistry
Hypothesis
Does azathioprine-associated mutagenesis contribute to the high incidence of skin tumors in organ transplant recipients?
Conclusion
The study suggests that azathioprine exposure may be associated with specific PTCH mutations in basal cell carcinomas, particularly in tumors from non-sun-exposed skin.
Supporting Evidence
- PTCH mutations were detected in 33 out of 60 (55%) BCC overall.
- Azathioprine exposure did not influence the frequency of PTCH mutations.
- Unusual G:C to A:T transitions at non-dipyrimidine sites were exclusive to the azathioprine-exposed group.
Takeaway
This study looked at skin cancer in organ transplant patients who took a medicine called azathioprine. It found that this medicine might change a gene that helps prevent cancer.
Methodology
The study analyzed PTCH gene mutations in 60 basal cell carcinomas from organ transplant recipients, comparing those treated with azathioprine to those not treated.
Potential Biases
Potential confounding factors include the use of other immunosuppressants and the inherent differences in skin cancer development between immunocompetent and immunosuppressed individuals.
Limitations
The study did not include a sufficient number of non-sun-exposed BCCs from immunocompetent individuals for meaningful comparison.
Participant Demographics
The study included 60 BCCs from 58 individuals, with 38 organ transplant recipients and 20 immunocompetent individuals.
Statistical Information
P-Value
0.042
Statistical Significance
p=0.042
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website